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OBJECTIVE — To investigate renal elimination of the adipokine ﬁbroblast growth factor 21
(FGF21) by determining circulating FGF21 levels in patients on chronic hemodialysis (CD) as
compared with control subjects with a glomerular ﬁltration rate (GFR) 50 ml/min.
RESEARCH DESIGN AND METHODS — FGF21 was determined by enzyme-linked
immunosorbentassayincontrol(n60)andCD(n60)patientsandcorrelatedtoclinicaland
biochemicalmeasuresofrenalfunction,glucoseandlipidmetabolism,andinﬂammationinboth
groups.
RESULTS — MedianserumFGF21levelswere15-foldhigherinCDpatients(3,710.6ng/l)
than in subjects with a GFR 50 ml/min (201.9 ng/l) (P  0.001). Furthermore, serum creat-
inine positively and GFR negatively predicted FGF21 concentrations in multiple regression
analyses in control subjects (P  0.05).
CONCLUSIONS — FGF21 serum levels increase in CD patients and are related to markers
of renal function in control subjects.
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R
ecently, ﬁbroblast growth factor 21
(FGF21) was introduced as a novel
adipokine with potent antidiabetic
properties (1–4). In contrast to extensive
experimentsinanimals,onlyonestudyto
date has determined regulation and func-
tion of FGF21 in humans in vivo (5),
and no data have been published about
the relation of this adipokine to renal
function.
RESEARCH DESIGN AND
METHODS— The design of the study
has been described in detail recently (6–
8). Brieﬂy, 120 Caucasian men (n  62)
and women (n  58) were recruited with
60 patients having a glomerular ﬁltration
rate(GFR)50ml/min(controlsubjects)
asassessedbytheoriginalModiﬁcationof
Diet in Renal Disease formula (9) and 60
patients being on chronic hemodialysis
(CD).Atotalof30controlsubjectsand32
CD patients had type 2 diabetes. The
study was approved by the local ethics
committee, and all subjects gave written
informed consent before taking part in
the study.
Assays
Bloodsamplesweretakenafteranovernight
fast. In CD patients, blood was drawn just
before hemodialysis started. FGF21 (Bio-
vendor, Modrice, Czech Republic), adi-
ponectin (Mediagnost, Reutlingen,
Germany), and leptin (Mediagnost) were
determined with enzyme-linked immu-
nosorbentassaysaccordingtothemanufac-
turer’s instructions.
Statistical analysis
Statistical analyses are speciﬁed in RESULTS
and in the Table 1 legend.
RESULTS
FGF21 serum levels are increased in
CD patients
Table 1 summarizes clinical characteris-
tics of the subgroups studied (control,
CD) further divided into nondiabetic and
diabetic subjects. Median circulating
FGF21 was 15-fold higher in CD pa-
tients(3,710.65,541.3ng/l)compared
with control subjects (201.9  275.5
ng/l)(P0.001)(Table1).Furthermore,
FGF21 serum levels were signiﬁcantly
higher in men (1,959.0  4,505.5 ng/l)
compared with women (446.9  1,609.0
ng/l) (P  0.05) but did not depend on
type 2 diabetes.
Univariate correlations
Using the Spearman’s rank correlation
method, serum FGF21 concentrations
positively correlated with BMI (r  0.33,
95% CI 0.08–0.54, P  0.011) and cre-
atinine (r  0.32, 0.07–0.53, P  0.014)
in control subjects. In addition, FGF21
negatively correlated with LDL choles-
terol (r  0.33, 0.08 to 0.54, P 
0.010) and GFR (r  0.26, 0.01 to
0.49, P  0.041) in control patients. In
CD patients, circulating FGF21 levels
were positively associated with waist-to-
hip ratio (r  0.29, 0.03–0.50, P 
0.027) and fasting glucose (r  0.33,
0.09–0.54, P  0.009).
Multivariate regression analyses
Multiple linear regression analysis re-
vealed that creatinine ( coefﬁcient
0.361, 95% CI 0.088–0.634, P  0.011)
and LDL cholesterol ( coefﬁcient
0.413, 0.660 to 0.166, P  0.001)
remained independently associated with
circulating FGF21 levels in control sub-
jects after adjustment for sex, BMI, and
type2diabetes.WhenGFRinsteadofcre-
atinine was included in this multivariate
analysis, GFR remained independently
associated with serum FGF21 concentra-
tions ( coefﬁcient 0.296, 0.529 to
0.063, P  0.014). Furthermore, creat-
inine and GFR remained signiﬁcant inde-
pendent predictors of circulating FGF21
in diabetic control subjects (P  0.05),
and a trend toward an independent asso-
ciationofcreatinineandGFRwithFGF21
levels was also observed in nondiabetic
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shown).InCDpatients,fastingglucose(
coefﬁcient 0.354, 0.090–0.618, P 
0.009) predicted circulating FGF21 inde-
pendent of sex, waist-to-hip ratio, GFR,
and type 2 diabetes. However, an associ-
ation between creatinine and GFR on one
handandFGF21ontheotherhandcould
not be shown in CD patients in univariate
and multivariate analyses.
CONCLUSIONS — In the current
study, the hypothesis that renal elimina-
tion is a major route by which physiolog-
ical FGF21 serum levels are maintained is
supported by two novel ﬁndings. First,
we demonstrate that both creatinine and
GFR are signiﬁcantly associated with cir-
culating FGF21 in control subjects with a
GFR 50 ml/min independent of sex,
BMI,LDLcholesterol,andtype2diabetes
in multivariate analysis. Furthermore, we
show that FGF21 is increased 15-fold in
CD patients, i.e., in patients with severely
impaired renal function. Based on the re-
sults of our study, serum creatinine or
othermarkersofrenalfunctionshouldal-
ways be included in future studies con-
cerning FGF21 physiology.
Adiponectin serum levels are signiﬁ-
cantlyincreasedinCDpatientscompared
withcontrolsubjectsinthecurrentstudy.
These results support previous ﬁndings
(10–12) that renal elimination contrib-
utes to circulating concentrations of this
adipokine.
Circulating FGF21 and adiponectin
are slightly but signiﬁcantly higher after
as compared with before hemodialysis in
a subset of the CD patients (n  29) re-
cruited again 2 years after blood was
obtained for this study (data not shown).
Theseresultssupportthenotionthatboth
adipokines are not dialyzable.
The physiological signiﬁcance of in-
creased FGF21 serum concentrations in
renalfailureremainstobeelucidated.Itis
interesting to note that circulating FGF21
isalsosigniﬁcantlyhigherinanotherpop-
ulation with increased cardiovascular
risk, i.e., patients exhibiting components
of the metabolic syndrome (5). Because
FGF21 is an adipokine with glucose-
lowering effects (1–4), it is tempting to
speculate that paradoxical increase of this
proteinincardiovascularriskpopulations
isacompensatorymechanismtocounter-
actmetabolicstress.Alternatively,FGF21
resistance might be found in obesity and
renalfailure,leadingtocompensatoryup-
regulation of this adipokine. This mecha-
nism would be reminiscent of
hyperinsulinemia and hyperleptinemia,
which are a consequence of increased
production in compensation for obesity-
associated resistance to insulin and leptin
(13). Here, further studies are needed to
investigate whether subjects and animal
models with obesity and renal failure ex-
hibitdecreasedFGF21sensitivityandim-
paired receptor or postreceptor signaling
initstargettissues.Inaddition,adiponec-
tinresistancehasbeendescribedindiffer-
entanimalmodels(14,15)andmightplay
a role in upregulation of adiponectin in
CD patients.
Some limitations of the study have to
be pointed out. First, there is a risk of
overﬁtting the multivariate models since
our study is limited by a relatively small
sample size. Furthermore, it remains un-
clear at present why creatinine and GFR
are not independently correlated to
FGF21levelsinCDpatientsincontrastto
the results obtained in control subjects. It
is tempting to speculate that mechanisms
besides renal elimination contribute to
FGF21regulationinCD,sincerenalfunc-
tionisseverelyimpairedinthesepatients.
Table 1—Baseline characteristics of the study population
Control/T2DM
 Control/T2DM
 CD/T2DM
 CD/T2DM

n 30 30 28 32
FGF21 (ng/l) 195.1  239.9 207.6  384.1 3,825.1  5,593.9 3,593.8  6,562.2
Age (years) 63  19 63  16 59  23 68  12
Sex (M/F) 11/19 16/14 15/13 20/12
BMI (kg/m
2) 28.2  5.6 29.1  5.2 25.2  6.5*† 27.9  6.6
Waist-to-hip ratio 0.88  0.12 0.94  0.10* 0.96  0.18 1.00  0.14*
Systolic blood pressure (mmHg) 125  21 126  20 125  38 120  25
Diastolic blood pressure (mmHg) 77  10 73  15 77  20 70  18
Creatinine (	mol/l) 76  17 72  22 829  431*† 717  221*†
Albumin (g/l) 46.2  3.7 46.5  3.4 41.6  4.9*† 41.3  4.9*†
Urea (mmol/l) 5.1  1.5 5.3  2.1 17.1  7.4*† 18.7  7.9*†
GFR (ml/min) 82.5  23.9 89.3  35.5 7.0  4.0*† 7.6  3.2*†
Fasting glucose (mmol/l) 5.1  1.3 7.6  3.2* 4.6  1.2† 5.2  3.3†‡
Fasting insulin (pmol/l) 45.1  33.3 47.9  62.6 28.2  47.6 50.1  91.6
HOMA-IR 1.4  1.2 2.8  3.0 0.8  1.4† 1.4  3.3
Free fatty acid (mmol/l) 0.5  0.2 0.6  0.4 0.6  0.5 0.7  0.5
Cholesterol (mmol/l) 5.3  0.9 4.9  1.5 4.4  1.1* 4.2  1.3*
HDL cholesterol (mmol/l) 1.4  0.4 1.2  0.5 1.0  0.5*† 1.0  0.3*†
LDL cholesterol (mmol/l) 3.5  1.1 2.9  0.9
1 2.7  0.9* 2.1  1.4*†
Triglycerides (mmol/l) 1.1  0.8 1.4  0.9 1.6  0.9* 1.8  1.4*
Adiponectin (mg/l) 6.8  3.8 4.6  4.8 14.3  15.7*† 11.4  12.6*†
Leptin (	g/l) 17.8  25.4 16.8  22.3 11.4  35.1 28.0  54.4†‡
C-reactive peptide (mg/l) 2.5  4.4 2.8  3.8 3.5  11.9 6.9  24.7*†
Data are median  interquartile range. The groups are divided into control subjects without diabetes (control/T2DM
) or with diabetes (control/T2DM
)
and CD patients without diabetes (CD/T2DM
) or with diabetes (CD/T2DM
). HOMA-IR, homeostasis model assessment of insulin resistance. Parameters
were analyzed by the Kruskal-Wallis test followed by Bonferroni’s post hoc analysis. *P  0.05 vs. Control/T2DM
,† P  0.05 vs. Control/T2DM
,‡ P 
0.05 vs. CD/T2DM
.
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